Results 261 to 270 of about 3,038,180 (280)
Formation of the six-helix bundle (6-HB) core between the N- and C-terminal heptad repeats (NHR and CHR) regions of the HIV-1 envelope glycoprotein (Env) transmembrane subunit gp41 is a critical step during the process of virus and target cell membrane fusion.
Jiang Shibo, Ying-Hua Chen
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Fusion Core Complex of the Peste des Petits Ruminants Virus Is a Six-Helix Bundle Assembly
Biochemistry, 2003We describe the properties of the two heptad repeats (HR1 and HR2) of the Peste des petits ruminants virus (PPRV) fusion protein (F) to obtain insights into the mechanism by which these repeats influence PPRV-mediated cell fusion. Both HR1 and HR2 inhibit PPRV-mediated syncytia formation in Vero cells in vitro.
Rahaman, Abdur +3 more
openaire +2 more sources
AI-Guided Hydrophobic Core Design of Robust Six-Helix Bundle Proteins
ACS Nanoα-Helical domains are widespread and versatile, yet typically fail under low mechanical load because backbone hydrogen bonds unzip sequentially, limiting their use in force-bearing nanomaterials and molecular devices. We present an AI-guided strategy to design six-helix bundle proteins with densely packed hydrophobic cores that co-optimize mechanical ...
Yinying Meng +6 more
openaire +2 more sources
Broad-spectrum coronavirus inhibition by RSV fusion inhibitors targeting six-helix bundle formation
Life SciencesWaning vaccine-derived immunity and the emergence of new SARS-CoV-2 subvariants continue to challenge global public health, emphasizing the need for novel inhibitors against SARS-CoV-2 infection. Molecular inhibitors targeting virus entry are promising candidates as they can disrupt viral replication at the earliest stage.
Weiyi, Chen +7 more
openaire +2 more sources
Biochemistry, 2008
Enfuvirtide (ENF), the first human immunodeficiency virus type 1 (HIV-1) fusion inhibitor approved for clinical use, acts by binding to gp41 heptad repeat 1 (HR1) and preventing its interaction with the viral HR2 region. Treatment-emergent resistance to ENF has been mapped to residues within HR1, and these mutations decrease its susceptibility to ENF ...
Xuefang, Bai +13 more
openaire +2 more sources
Enfuvirtide (ENF), the first human immunodeficiency virus type 1 (HIV-1) fusion inhibitor approved for clinical use, acts by binding to gp41 heptad repeat 1 (HR1) and preventing its interaction with the viral HR2 region. Treatment-emergent resistance to ENF has been mapped to residues within HR1, and these mutations decrease its susceptibility to ENF ...
Xuefang, Bai +13 more
openaire +2 more sources
AIDS Research and Human Retroviruses, 2004
The HIV-1 envelope glycoprotein complex (Env) can be stabilized by the introduction of a disulfide bond between the gp120 and gp41 subunits. The resulting protein is monomeric, but trimerization can be improved by the introduction of a single helix-breaking residue at the conserved Ile559 site in the N-terminal heptad repeat region of gp41.
Sanders, Rogier W. +4 more
openaire +3 more sources
The HIV-1 envelope glycoprotein complex (Env) can be stabilized by the introduction of a disulfide bond between the gp120 and gp41 subunits. The resulting protein is monomeric, but trimerization can be improved by the introduction of a single helix-breaking residue at the conserved Ile559 site in the N-terminal heptad repeat region of gp41.
Sanders, Rogier W. +4 more
openaire +3 more sources
Biochemistry, 2003
In models of HIV fusion, the glycoprotein gp41 is thought to form a six-helix bundle during viral fusion with the target cell. This bundle is comprised of three helical regions (from the heptad repeat 2, or HR2, region of gp41) bound to an inner, trimeric, coiled-coil core (from the HR1 region).
John J, Dwyer +5 more
openaire +2 more sources
In models of HIV fusion, the glycoprotein gp41 is thought to form a six-helix bundle during viral fusion with the target cell. This bundle is comprised of three helical regions (from the heptad repeat 2, or HR2, region of gp41) bound to an inner, trimeric, coiled-coil core (from the HR1 region).
John J, Dwyer +5 more
openaire +2 more sources
Life Sciences, 2002
An increasing portion of patients with HIV infection and/or AIDS cannot use currently FDA-approved anti-HIV drugs, including the reverse transcriptase and protease inhibitors, due to the adverse effects and the emergence of drug resistance. Thus, it is essential to develop new anti-HIV agents with a target different from the HIV reverse transcriptase ...
Shuwen, Liu +6 more
openaire +2 more sources
An increasing portion of patients with HIV infection and/or AIDS cannot use currently FDA-approved anti-HIV drugs, including the reverse transcriptase and protease inhibitors, due to the adverse effects and the emergence of drug resistance. Thus, it is essential to develop new anti-HIV agents with a target different from the HIV reverse transcriptase ...
Shuwen, Liu +6 more
openaire +2 more sources
Current opinion in investigational drugs (London, England : 2000), 2006
Class I viral fusion proteins have an important role in the fusion of viral membranes with host cell membranes, a critical step in the viral life-cycle. These proteins all have similar structural features and form six-helix bundles in their fusogenic form, a general mechanism of action for virus-cell fusion.
openaire +1 more source
Class I viral fusion proteins have an important role in the fusion of viral membranes with host cell membranes, a critical step in the viral life-cycle. These proteins all have similar structural features and form six-helix bundles in their fusogenic form, a general mechanism of action for virus-cell fusion.
openaire +1 more source
Putative Inhibitors for Six-Helix Bundle Post-Fusion Complex of COVID-19 Disease Virus
International Journal of Pharmaceutical Research, 2020openaire +1 more source

